摘要

Objectives: As we age, lipid metabolism changes so that excess adipose tissue is stored as visceral fat rather than subcutaneous fat. While many claim that skin is the largest human organ, in many people the volume of fat far surpasses the volume of skin. Visceral fat behaves quite differently than subcutaneous fat, and alteration in free fatty acid synthesis and storage, changes in insulin sensitivity, and increases in % body fat and BMI with associated skeletal muscle mass loss can influence the development of metabolic syndrome and overall longevity. Introduction: There are currently no good solutions for visceral fat. While diet and exercise are recommended, no long term effective program currently exists. Semaglutide injections target subcutaneous fat as well as muscle mass. HIFEM plus RF can decrease visceral fat by 15-20% 3 months post-treatment, but these changes are hard to maintain. A prospective study utilizing a new topically applied serum was studied in fifteen qualified patients was performed in order to test a topical supplement. Materials / method: Fifteen patients ages 30-75 enrolled in a prospective study in which a topical serum targeted towards improving lipid metabolism was applied to the abdomen twice a day. Parameters measured included a comprehensive metabolic blood profile, 2D and 3D photos, bioimpedance analysis, and waist circumference. Bioimpedance analysis measured weight, BMI, % body fat, skeletal muscle mass, and visceral fat in cm2. These parameters were measured before treatment inception and at 1 month and 2 months post daily treatment. A daily journal was kept in order to application and to note any adverse effects. Results: All patients noted improvement but results varied from mild to dramatic improvement in the following parameters: visceral fat reduction, % body fat reduction, retention or enhancement of skeletal muscle mass, and improvement of lipid metabolism. Common changes in lipid measurements: decrease in serum triglycerides, increase in HDL, decrease in total cholesterol and LDL. Fasting glucose measurements were not significantly affected. Clinical improvement included a decrease in subcutaneous fat in the abdominal region and decrease in profile protrusion of the abdomen. No adverse events occurred. Conclusion: Age accumulated visceral fat and associated metabolic syndrome affect 41.6 million Americans. A promising topical serum has been developed that primarily affects the AMPK pathway targets aging lipid metabolism and when used regularly can decrease the risk of metabolic syndrome.